skip to main content

Resolved intrahepatic cholestasis of pregnancy in a breastfeeding woman requesting combined hormonal contracep

Instant feedback + full explanation. One question, done properly.

EasyObstetric CholestasisResolved intrahepatic cholestasis of pregnancy in a breastfeeding woman requesting combined hormonal contraceptionDFSRH

A 30-year-old woman requests combined oral contraception 8 weeks after an uncomplicated vaginal birth. She is primarily breastfeeding. During pregnancy, she had severe intrahepatic cholestasis of pregnancy, with a peak bile acid concentration of 112 micromol/L. At her 6-week postnatal review, pruritus had resolved and repeat liver function tests and bile acids were normal. She has a BMI of 23 kg/m², does not smoke and has no additional venous thromboembolism risk factors, hypertension or migraine. She previously used combined oral contraception without adverse effects and wishes to restart it. Which is the most appropriate contraceptive management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Initiate combined hormonal contraception now, advising prompt review if pruritus recurs

Explanation lettering: C = shown as A · A = shown as B · D = shown as C · E = shown as D · B = shown as E

Her pregnancy-related cholestasis has clinically and biochemically resolved. RCOG advises that intrahepatic cholestasis of pregnancy does not restrict subsequent contraceptive choice once liver function tests and bile acids have returned to normal; a user of estrogen-containing contraception should seek review if pruritus develops. She is primarily breastfeeding but is more than 6 weeks postpartum. Combined hormonal contraception is UKMEC 2 from 6 weeks to under 6 months in a primarily breastfeeding woman, so its advantages generally outweigh theoretical or proven risks. In the absence of other contraindications, it can therefore be initiated following routine counselling. B is incorrect because breastfeeding does not require deferral until 6 months; that point marks transition to UKMEC 1 rather than the earliest acceptable use. C is incorrect because neither a severe peak bile acid concentration nor an arbitrary 12-week interval requires additional delay after biochemical resolution. D is plausible because estrogen can be associated with cholestasis, but previous pregnancy-related cholestasis is not a permanent estrogen contraindication. E is unnecessary because her symptoms, liver tests and bile acids are already normal. Persistent pruritus or abnormal results at the 6-week review would instead warrant further investigation before estrogen-containing contraception is considered.

Reference: Intrahepatic cholestasis of pregnancy (Updated April 2026) — https://www.rcog.org.uk/for-the-public/browse-our-patient-information/intrahepatic-cholestasis-of-pregnancy/ FSRH Guideline: Combined Hormonal Contraception (October 2023) — https://www.fsrh.org/Common/Uploaded%20files/documents/fsrh-guideline-combined-hormonal-contraception-october-2023.pdf